Clinical Research Areas

Hematologic Malignancies

The OSUCCC – James is home to an internationally renowned center for hematologic malignancy treatment and research.

Hematologic Malignancies

Transdisciplinary teams of hematologists, oncologists, mid-level practitioners, researchers, nurses and other experts specialize in distinct hematologic malignancies, including:

Ohio State’s distinguished history in leukemia research began in 1958, when Dr. Bertha Bouroncle identified the cell responsible for hairy cell leukemia, a rare chronic leukemia.

Today, millions of dollars in research grants, including multiple grants from the National Cancer Institute and from the Leukemia and Lymphoma Society, support OSUCCC – James studies into how blood cancers develop and into identifying promising investigational treatments.

Hundreds of clinical trials under way at the OSUCCC – James enable us to provide patients with the latest advances in detecting and treating hematologic malignancies.

Acute Myeloid Leukemia

Learn how bench-to-bedside clinical research is being conducted at the OSUCCC – James to improve prevention, detection and treatment of acute myeloid leukemia.

Blood and Marrow Transplantation

The Blood and Marrow Transplant (BMT) Program research experts at the OSUCCC – James are internationally known and recognized for their pioneering, science-based advancements in treating cancer.

Chronic Lymphocytic Leukemia Clinical Research

The internationally renowned experts at the OSUCCC – James leukemia and hematologic malignancies program are dedicated to developing and conducting basic, translational, clinical and outcome-based research that advances innovative breakthroughs and treatments for patients with chronic lymphocytic leukemia (CLL).

Lymphoma Research

The internationally renowned experts in the OSUCCC – James lymphoma research program are dedicated to developing and conducting basic, translational, clinical and outcome-based research that advances innovative breakthroughs and treatments for patients with lymphoid malignancies.